NVIDIA
NVDA
Palantir
PLTR
Tesla
TSLA
4
Hims & Hers Health
HIMS
5
Alibaba
BABA
US Stock MarketDetailed Quotes
PFE Pfizer
- 26.650
- +0.350+1.33%
Close Feb 24 16:00 ET
- 26.580
- -0.070-0.26%
Pre 06:04 ET
151.03BMarket Cap18.90P/E (TTM)
26.740High25.880Low43.82MVolume26.400Open26.300Pre Close1.16BTurnover0.77%Turnover Ratio18.90P/E (Static)5.67BShares30.55252wk High1.64P/B150.80BFloat Cap23.71352wk Low1.68Dividend TTM5.66BShs Float53.002Historical High6.30%Div YieldTTM3.27%Amplitude5.306Historical Low26.448Avg Price1Lot Size
Pfizer Stock Forum
Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment?
A nice double bottom pattern in the chart. The stock is trading above 5 EMA, 10 EMA, 20 EMA, 60 EMA and 120 EMA. The trend is up. Once it breaks above $27, the trend is confirmed bullish.
Chart looks good. Next resistance is 26.47. Once it breaks the resistance, next hit point will be 26.69.
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.
Miami biopharmaceutical company Summit said it will provide ivonescimab for...
Can This New Summit-Pfizer Cancer Drug Combo Transform Solid Tumor Treatment?
Show time
US and Australian markets are bracing for a pullback after US big tech stocks have already wiped off US$721 billion in value, with the biggest US tech stocks in the Nasdaq-100 $NASDAQ 100 Index (.NDX.US)$ shedding 2.1% on Friday and the S&P 500 $S&P 500 Index (.SPX.US)$ losing 1.7%. He...
No comment yet